Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) EBITDA (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed EBITDA for 4 consecutive years, with -$53.9 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA fell 28.09% to -$53.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$242.2 million, a 51.42% decrease, with the full-year FY2024 number at -$233.0 million, down 57.36% from a year prior.
  • EBITDA was -$53.9 million for Q3 2025 at Centessa Pharmaceuticals, down from -$50.8 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$23.3 million in Q2 2023 to a low of -$109.2 million in Q4 2024.
  • A 4-year average of -$48.8 million and a median of -$43.8 million in 2024 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: soared 64.52% in 2023, then plummeted 202.33% in 2024.
  • Centessa Pharmaceuticals' EBITDA stood at -$43.0 million in 2022, then grew by 15.94% to -$36.1 million in 2023, then tumbled by 202.33% to -$109.2 million in 2024, then skyrocketed by 50.66% to -$53.9 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's EBITDA are -$53.9 million (Q3 2025), -$50.8 million (Q2 2025), and -$28.3 million (Q1 2025).